The Brazil Metabolic Disorders Therapeutics market size stood at around USD xx billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.
Metabolic disorders usually occur due to disruption of the normal processes of the body. These disorders can be hereditary or acquired and the symptoms differ from person to person. Some metabolic disorders cause mild symptoms that can be managed with slight medication and lifestyle changes, whereas few can cause life-threatening symptoms, such as breathing problems, seizure, and organ failure.
Due to the patient assistance programs by Brazilian government and SUS initiative the treatment for a range of metabolic disorders have become faster and easier. Also, the rise in awareness about the availability of therapeutics are primary factors for driving the market growth.
Moreover, the advancement in technology and increase in funding for the development of novel therapeutic has acted like a catalyst for further boosting the market.
Major Metabolic Disorders
Based on diseases, the market is categorized into diabetes, lysosomal disorders, hypercholesterolemia, obesity, and inherited metabolic disorders. These types of diseases are mostly inherited via a faulty gene.
Among them, diabetes is estimated to be the largest segment due to the wide usage of metabolic disease therapies in anti-diabetic drugs and injections to control the blood sugar levels., which makes it the largest revenue-generating segment. Moreover, the obesity segment is expected to witness the highest CAGR over the forecast period due to change lifestyle changes and unhealthy eating habits, especially among children. It is observed that 74.0% of children with obesity consumed fried foods and sweets at school, and 84.0% consumed snacks and soft drinks at home.